Adverse effects of GLP-1 receptor agonists: difference between revisions
Diff·revision 19 → 20·06:48, 17 Feb 2025
Difference between revision 19 and revision 20 of Adverse effects of GLP-1 receptor agonists. 2 lines changed; the page grew by 213 bytes.
| Revision 19 — 14:42, 2 Feb 2025 DrTitration (talk) correct the percentage — source reports it per patient-year 4,482 bytes ±0 | Revision 20 — 06:48, 17 Feb 2025 LeanMassLars (talk) fix hyphenation per PP:MOS 4,695 bytes +213 | ||
|---|---|---|---|
| 34 | The medullary thyroid carcinoma contraindication derives from rodent C-cell hyperplasia and tumours at high exposure. Rodent C cells express the receptor at much higher density than human C cells, and no human signal has been established; the contraindication is precautionary. See [[Medullary thyroid carcinoma]].{{r|drucker2018}} | 34 | The medullary thyroid carcinoma contraindication derives from rodent C-cell hyperplasia and tumours at high exposure. Rodent C cells express the receptor at much higher density than human C cells, and no human signal has been established; the contraindication is precautionary. See [[Medullary thyroid carcinoma]].{{r|drucker2018}} |
| 35 | 35 | ||
| + | 36 | A signal for non-arteritic anterior ischaemic optic neuropathy has been reported in observational data and remains under evaluation; observational designs cannot exclude confounding by indication.{{r|nauck2016}} | |
| + | 37 | ||
| 36 | == References == | 38 | == References == |
| 37 | {{reflist}} | 39 | {{reflist}} |